Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 6 | 2023 | 230 | 1.890 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2015 | 28 | 0.560 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 229 | 0.550 |
Why?
|
| Aromatase Inhibitors | 2 | 2015 | 51 | 0.550 |
Why?
|
| Physicians | 1 | 2023 | 866 | 0.450 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 312 | 0.410 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 998 | 0.400 |
Why?
|
| Bone and Bones | 1 | 2013 | 294 | 0.350 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 2133 | 0.280 |
Why?
|
| Arthropathy, Neurogenic | 1 | 2007 | 2 | 0.280 |
Why?
|
| Diabetes Complications | 1 | 2007 | 224 | 0.240 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2023 | 46 | 0.200 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 79 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2025 | 2442 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 5415 | 0.160 |
Why?
|
| Family Practice | 1 | 2023 | 455 | 0.150 |
Why?
|
| Aged | 7 | 2025 | 22061 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 250 | 0.140 |
Why?
|
| Hyperparathyroidism | 1 | 2017 | 11 | 0.140 |
Why?
|
| RNA Splice Sites | 1 | 2017 | 44 | 0.140 |
Why?
|
| Blood Glucose | 2 | 2025 | 2100 | 0.140 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2017 | 34 | 0.130 |
Why?
|
| Abdominal Fat | 1 | 2017 | 40 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2023 | 1271 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 32 | 0.130 |
Why?
|
| Bone Density Conservation Agents | 2 | 2019 | 70 | 0.130 |
Why?
|
| Hyperglycemia | 1 | 2020 | 327 | 0.130 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 77 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 670 | 0.130 |
Why?
|
| Diphosphonates | 2 | 2013 | 58 | 0.130 |
Why?
|
| Point Mutation | 1 | 2017 | 224 | 0.130 |
Why?
|
| SEER Program | 1 | 2017 | 202 | 0.130 |
Why?
|
| Bone Density | 2 | 2017 | 463 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 340 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.120 |
Why?
|
| Muscle Weakness | 1 | 2016 | 85 | 0.120 |
Why?
|
| Hand Strength | 1 | 2016 | 113 | 0.120 |
Why?
|
| Carcinoma | 1 | 2017 | 214 | 0.120 |
Why?
|
| Osteochondroma | 1 | 2015 | 7 | 0.120 |
Why?
|
| Toes | 1 | 2015 | 15 | 0.120 |
Why?
|
| Middle Aged | 9 | 2025 | 31136 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 314 | 0.120 |
Why?
|
| Humans | 17 | 2025 | 129625 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 155 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1213 | 0.100 |
Why?
|
| Mass Screening | 1 | 2020 | 1190 | 0.100 |
Why?
|
| Male | 10 | 2025 | 63670 | 0.100 |
Why?
|
| Adiposity | 1 | 2017 | 504 | 0.100 |
Why?
|
| Cartilage, Articular | 1 | 2015 | 292 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 7052 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 2011 | 0.080 |
Why?
|
| Survival Rate | 1 | 2013 | 1872 | 0.080 |
Why?
|
| Potassium | 1 | 2009 | 144 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 1001 | 0.070 |
Why?
|
| Adult | 5 | 2017 | 35599 | 0.070 |
Why?
|
| Blood Sedimentation | 1 | 2007 | 34 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2009 | 306 | 0.070 |
Why?
|
| Cellulitis | 1 | 2007 | 49 | 0.070 |
Why?
|
| Hypolipidemic Agents | 1 | 2007 | 92 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2007 | 98 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2007 | 326 | 0.060 |
Why?
|
| Edema | 1 | 2007 | 124 | 0.060 |
Why?
|
| United States | 1 | 2023 | 13871 | 0.060 |
Why?
|
| Female | 7 | 2025 | 68734 | 0.060 |
Why?
|
| Foot | 1 | 2007 | 93 | 0.060 |
Why?
|
| Exercise | 1 | 2017 | 1928 | 0.060 |
Why?
|
| Hypoglycemic Agents | 2 | 2025 | 1221 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 797 | 0.060 |
Why?
|
| Risk Factors | 2 | 2016 | 9786 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 485 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 430 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 679 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1432 | 0.050 |
Why?
|
| Quality of Life | 1 | 2013 | 2688 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2007 | 394 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 2046 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 3394 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2025 | 601 | 0.040 |
Why?
|
| Hypertension | 1 | 2007 | 1243 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2016 | 138 | 0.030 |
Why?
|
| Anthropometry | 1 | 2016 | 204 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 735 | 0.030 |
Why?
|
| Hospitalization | 1 | 2025 | 2057 | 0.030 |
Why?
|
| Income | 1 | 2016 | 188 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1491 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1501 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 234 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1970 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 3152 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2274 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 14522 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2009 | 402 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 1986 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 1021 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 12455 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 1736 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 5426 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 10219 | 0.010 |
Why?
|